Philadelphia Chromosome Positive clinical trials

Explore recruiting philadelphia chromosome positive clinical trials.

Recruiting philadelphia chromosome positive studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Philadelphia Chromosome Positive trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Germany, Sweden, Denmark, Italy, Austria, Czechia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemias Resistant or Intolerant to Imatinib.

France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

France, Lithuania, Norway, Finland, Spain, Italy +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)

Hungary, France, Romania, Czechia, Italy, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase

Bulgaria, Austria, Czechia, Portugal, Hungary, Norway +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Philadelphia Chromosome Positive trials by city

Philadelphia Chromosome Positive in Toronto Philadelphia Chromosome Positive in Vancouver Philadelphia Chromosome Positive in Montreal Philadelphia Chromosome Positive in Calgary Philadelphia Chromosome Positive in Edmonton Philadelphia Chromosome Positive in Ottawa Philadelphia Chromosome Positive in Winnipeg Philadelphia Chromosome Positive in Quebec City Philadelphia Chromosome Positive in Hamilton Philadelphia Chromosome Positive in Kitchener Philadelphia Chromosome Positive in London Philadelphia Chromosome Positive in Halifax Philadelphia Chromosome Positive in New York Philadelphia Chromosome Positive in Los Angeles Philadelphia Chromosome Positive in Chicago Philadelphia Chromosome Positive in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease